June 30 (Reuters) - AbbVie (ABBV.N), opens new tab said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its product ...

AbbVie has agreed to acquire Capstan Therapeutics for up to $2.1bn, adding a “high-risk, high-reward” clinical-stage in vivo CAR-T candidate to its pipeline. Capstan is developing a new type of CAR-T ...

AbbVie is making a full strength play for the in vivo CAR-T market, snapping up Capstan Therapeutics for $2.1 billion to add an early-phase autoimmune drug candidate to its pipeline. Capstan is part ...

AbbVie (ABBV) on Monday announced that it has entered into a definitive agreement to acquire privately held clinical-stage biotechnology company Capstan Therapeutics, Inc., in a bid to boost its ...

AbbVie wasn’t part of the first wave of cell therapies developed for cancer, but it is positioning itself to contend in the next one, which is expanding to therapies made by engineering immune cells ...

CPTX2309 is a targeted lipid nanoparticle that delivers an anti-CD19 CAR mRNA preferentially to CD8-expressing cytotoxic T cells mRNA-based approach is designed to achieve rapid, deep, and transient B ...

SAN DIEGO--(BUSINESS WIRE)--Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery utilizing targeted lipid ...

U.S. drugmaker AbbVie said on Monday it will acquire cell therapy developer Capstan Therapeutics in a cash deal worth up to $2.1 billion, expanding its pipeline with experimental treatments for ...